Sanofi sells the product in vials (Lantus) and as a disposable injection pen (Lantus SoloSTAR®). About Mylan Mylan is a global pharmaceutical company committed to setting new standards in healthcare.

Mylan was not immediately available for comment. The 2017 case, which includes some patents covering a disposable injection pen version, Lantus SoloSTAR, is pending and no trial date has been set ...

Sanofi sells the product in vials (Lantus) and as a disposable injection pen (Lantus SoloSTAR®). Mylan's 505(b)(2) New Drug Application (NDA) for generic versions of Lantus and Lantus SoloSTAR ...

Mylan and Biocon's Semglee (insulin glargine ... mL Vial had a market value of approximately $1.68 billion, and Lantus SoloSTAR Pen had a market value of roughly $4.33 billion, for the 12 months ...

Last month, the PTAB invalidated the sole challenged claim of another Lantus SoloSTAR device patent, U.S. Patent No. 8,679,069, and, in March, Mylan announced that the U.S. District Court of New ...

Mylan was not immediately available for comment. The 2017 case, which includes some patents covering a disposable injection pen version, Lantus SoloSTAR, is pending and no trial date has been set ...

Last month, the PTAB invalidated the sole challenged claim of another Lantus SoloSTAR device patent, U.S. Patent No. 8,679,069, and, in March, Mylan announced that the U.S. District Court of New ...

Last month, the PTAB invalidated the sole challenged claim of another Lantus SoloSTAR device patent, U.S. Patent No. 8,679,069, and, in March, Mylan announced that the U.S. District Court of New ...

MYLAN - PTAB RULED IN FAVOR OF CO IN IPR PROCEEDINGS FINDING ALL CHALLENGED CLAIMS OF SANOFI'S LANTUS SOLOSTAR DEVICE PATENTS * MYLAN - PTAB FOUND THREE CLAIMS OF 9,604,008 PATENT UNPATENTABLE ...